Recent developments include shareholder approval and final court approval of the plan of arrangement with Hanmi Pharmaceutical, ongoing clinical trial progress with tuspetinib, and financial results reporting for year-end 2025.

• On March 31, 2026, Aptose announced the results of a special shareholders meeting, receipt of final court approval of the plan of arrangement with Hanmi Pharmaceutical, and reported year-end 2025 results and corporate highlights [N1].
• Leading independent proxy advisory firm ISS recommended shareholders vote "FOR" the proposed plan of arrangement with Hanmi Pharmaceutical in March 2026 [N2].
• In February 2026, Aptose announced an amendment to the arrangement agreement and details of a postponed special meeting of shareholders [N3].
• In December 2025, Aptose announced rescheduling of the special meeting of shareholders to approve the acquisition by Hanmi pending final clearance from the SEC [N4].
• Tuspetinib triple drug therapy was featured at the 2025 ASH Annual Meeting, showing a high rate of frontline clinical responses across AML populations [N5].
• In November 2025, Aptose announced the arrangement agreement for acquisition by Hanmi Pharmaceutical [N6].
• Aptose reported third quarter 2025 results in November 2025 [N7].
• In September 2025, Aptose and Hanmi Pharmaceutical extended their loan agreement to continue development of tuspetinib in triplet therapy for AML [N8].

Tuspetinib’s clinical data showing high remission rates and MRD negativity across diverse and difficult-to-treat AML mutations suggest potential for significant clinical impact. The drug’s favorable safety profile in combination therapies may enable its use in frontline AML treatment, second-line relapsed/refractory AML, and maintenance therapy. The exclusive global licensing agreement with Hanmi Pharmaceutical and the planned acquisition by Hanmi could provide resources and infrastructure to advance development and commercialization. Positive clinical milestones and regulatory approvals could enhance the company’s value proposition.

Aptose faces significant risks typical of clinical-stage biotechs, including the uncertainty of clinical trial outcomes, regulatory approvals, and commercial viability of tuspetinib. The company’s financial position shows liquidity constraints, with a current ratio below 1 and ongoing operating losses, raising concerns about its ability to sustain operations without additional financing. The acquisition arrangement is subject to customary closing conditions and regulatory approvals, with no assurance of completion. Competition from other therapies and potential delays or failures in clinical development could adversely affect the company’s prospects.

Aptose’s moat is based on its proprietary kinase inhibitor tuspetinib, which targets a select group of kinases operative in myeloid malignancies and is designed to avoid toxicities associated with other kinase inhibitors. The drug’s demonstrated activity against resistant AML mutations, including FLT3 ITD and TKD mutations, and its favorable safety profile in combination therapies provide a differentiated clinical profile. The exclusive licensing agreement with Hanmi Pharmaceutical and ongoing clinical development in frontline and relapsed AML settings further support its competitive positioning. However, as a clinical-stage biotech, the company faces competition from established pharmaceutical firms and other emerging therapies in hematologic oncology.

• Clinical Development Risk: Tuspetinib is in early clinical stages, and its safety and efficacy must be confirmed in larger trials. Failure to demonstrate clinical benefit or safety could halt development.
• Regulatory Approval Risk: Obtaining regulatory approvals is uncertain and subject to delays or denials, which could impact the company’s ability to commercialize tuspetinib.
• Financial and Liquidity Risk: The company has a working capital deficiency and relies on financing from Hanmi and equity issuances. Inability to secure sufficient funding could impair operations.
• Acquisition Completion Risk: The planned acquisition by Hanmi is subject to shareholder, regulatory, and other approvals. Failure to complete the transaction could adversely affect business and financial condition.
• Competitive Risk: The oncology therapeutics market is highly competitive with many companies developing treatments for AML and related diseases, which could limit market opportunities.

• Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on developing precision medicines for oncology, primarily hematologic cancers such as acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (hr-MDS).
• The company’s lead clinical asset is tuspetinib (HM43239), an oral once-daily kinase inhibitor targeting kinases involved in myeloid malignancies, designed to avoid toxicities common to other kinase inhibitors.
• Tuspetinib is being developed primarily as a frontline combination therapy with venetoclax and a hypomethylating agent (azacitidine) in newly diagnosed AML patients, investigated in the Phase 1/2 TUSCANY clinical trial.
• Clinical data from the TUSCANY trial show promising safety, tolerability, and efficacy, including high complete remission (CR/CRh) rates and minimal residual disease (MRD) negativity across diverse mutational subtypes, including difficult-to-treat mutations such as TP53, RAS, and FLT3.
• Tuspetinib monotherapy and combination therapies (TUS+VEN doublet and TUS+VEN+AZA triplet) have demonstrated favorable safety profiles with no dose-limiting toxicities, no drug-related QTc prolongations, differentiation syndrome, or myelosuppression in remission.
• The company has a licensing agreement with Hanmi Pharmaceutical granting Aptose exclusive worldwide rights to tuspetinib, with milestone payments and royalties contingent on clinical, regulatory, and sales achievements.
• Aptose entered into a definitive arrangement agreement with Hanmi Pharmaceutical for acquisition, with shareholders approving the plan in March 2026; the arrangement is subject to customary closing conditions and regulatory approvals.
• Financially, as of December 31, 2025, Aptose had cash and cash equivalents of $935,000, current assets of $6.45 million, current liabilities of $9.31 million, resulting in a current ratio of 0.69 and a cash ratio of 0.31, indicating liquidity constraints.
• The company reported a net loss of $25.47 million for the year ended December 31, 2025, with an EPS of -$10.41, reflecting ongoing operating losses typical of clinical-stage biotechs.
• Aptose relies on advances from Hanmi Pharmaceutical and equity financing to fund operations; the company has an uncommitted loan facility with Hanmi for up to $11.1 million to support clinical development and operations.
• The company’s securities are planned to be delisted from the Toronto Stock Exchange following the completion of the acquisition arrangement.
• Aptose employs 14 full-time employees as of December 31, 2025, including personnel with advanced degrees in medicine, science, and business.
• The company’s clinical development strategy includes positioning tuspetinib for frontline AML therapy, second-line therapy in relapsed/refractory AML, maintenance therapy post-remission, and treatment of hr-MDS.
• Recent corporate developments include shareholder meetings, appointment of Ernst & Young LLP as auditor, and amendments to the arrangement agreement with Hanmi Pharmaceutical.
• The company’s research and development expenses were $11.3 million in 2025, and general and administrative expenses were $13.4 million, reflecting increased legal and professional fees.
• Tuspetinib has shown preclinical activity against FLT3 ITD and TKD mutations, including resistance-conferring mutations, and inhibits kinases involved in tumor proliferation and resistance mechanisms.
• Clinical data presentations at major hematology conferences (ASH 2025, EHA 2025) have highlighted the safety and efficacy of tuspetinib triplet therapy in AML.
• The company’s ongoing clinical trials include dose escalation to 160 mg of tuspetinib in combination therapy cohorts.
• The company’s financial statements have been audited by Ernst & Young LLP, with disclosures about going concern risks due to recurring losses and working capital deficiencies.